CD274 and cancer: Immune checkpoint inhibitors (ICIs), which target molecules such as programmed death receptor-1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4), have shown promise in modulating the immune response to cancer cells [3].